Glymera

AssetAlso called PB1023, PF-1801

Long-acting GLP-1 receptor agonist fusion protein that stimulates glucose-dependent insulin secretion and improves glycemic control.

Stage
Phase 2, no development reported
Modality
Protein or enzyme
Target
Not known
1
Indication
2
Trials
1
Developer

No development reported since July 2013. Last activity: Trial NCT01658501 completed. clinicaltrials.gov

Indications

1

In the full profile

  • Owner and partners1
  • Trials2
  • Competitors12

Every asset’s record: target, stage, trials and the evidence behind it.

See Pro

Assets